Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IO Biotech, Inc.IOBT · Entity 8764 | Director | November 09, 2021 | November 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IO Biotech, Inc.
Report date November 09, 2021 · Filed November 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 796,059 |
Reported balance
After 2021-11-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-11-09 · Conversion · Acquired 796,059 · Balance 796,059 F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F2: The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 267,977 |
Reported balance
After 2021-11-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-11-09 · Conversion · Acquired 267,977 · Balance 267,977 F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F3: The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 958,559 |
Reported balance
After 2021-11-09 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-11-09 · Purchase · Acquired 162,500 · Balance 958,559 F2: The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 430,477 |
Reported balance
After 2021-11-09 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2021-11-09 · Purchase · Acquired 162,500 · Balance 430,477 F3: The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-11-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-09 · Conversion · Disposed 63,350 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F2: The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-11-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-09 · Conversion · Disposed 21,325 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F3: The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
F2: The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any.
F3: The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2021 Filed Nov 12, 2021 21:16 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionSeries C Preferred Stock · Derivative | 21,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-037655 · form4.xml · derivative · entry 6 Malier Vanessa · CIK 0001891515 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 267,977 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F3 · ownership.nature: The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:16 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionSeries C Preferred Stock · Derivative | 63,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-037655 · form4.xml · derivative · entry 5 Malier Vanessa · CIK 0001891515 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 796,059 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:16 UTC | IO Biotech, Inc. IOBT · Entity 8764 | PurchaseCommon Stock | 162,500 | $14.00 | $2,275,000.00 |
DisclosureSEC source: 0001140361-21-037655 · form4.xml · nonDerivative · entry 4 Malier Vanessa · CIK 0001891515 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 430,477 F3 · ownership.nature: The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:16 UTC | IO Biotech, Inc. IOBT · Entity 8764 | PurchaseCommon Stock | 162,500 | $14.00 | $2,275,000.00 |
DisclosureSEC source: 0001140361-21-037655 · form4.xml · nonDerivative · entry 3 Malier Vanessa · CIK 0001891515 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 958,559 F2 · ownership.nature: The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:16 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionCommon Stock | 267,977 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-037655 · form4.xml · nonDerivative · entry 2 Malier Vanessa · CIK 0001891515 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 267,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F3 · ownership.nature: The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:16 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionCommon Stock | 796,059 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-037655 · form4.xml · nonDerivative · entry 1 Malier Vanessa · CIK 0001891515 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 796,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.